We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-0.45%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.57B
AUM Growth
-$289M
Cap. Flow
-$161M
Cap. Flow %
-6.26%
Top 10 Hldgs %
55.83%
Holding
95
New
7
Increased
6
Reduced
12
Closed
24

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$265M
2
RLAY icon
Relay Therapeutics
RLAY
+$43.5M
3
FATE icon
Fate Therapeutics
FATE
+$28.3M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$16.3M
5
PMVP icon
PMV Pharmaceuticals
PMVP
+$13.8M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$89.2M
2
ARGX icon
argenx
ARGX
+$51.6M
3
CNTB
Connect Biopharma Holdings
CNTB
+$50.4M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$43.7M
5
FULC icon
Fulcrum Therapeutics
FULC
+$35.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.19%
2 Miscellaneous 11.98%
3 Financials 0.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAM
26
DELISTED
Avidity Biosciences
RNAM
$26.7M 1.04%
1,121,327
– –
BLU
27
DELISTED
BELLUS Health Inc.
BLU
$25.8M 1%
3,200,000
+225,000
+8% +$1.49M
GHRS icon
28
GH Research
GHRS
$1.9B
$23.6M 0.92%
1,013,399
– –
NUVL
29
DELISTED
Nuvalent
NUVL
$23M 0.89%
1,210,192
– –
IOVA icon
30
Iovance Biotherapeutics
IOVA
$4.42B
$21M 0.82%
1,100,000
– –
DAWN
31
DELISTED
Day One Biopharmaceuticals
DAWN
$20.1M 0.78%
1,189,943
– –
XENE icon
32
Xenon Pharmaceuticals
XENE
$5.56B
$18.7M 0.73%
600,000
-257,000
-30% -$7.68M
ALGS icon
33
Aligos Therapeutics
ALGS
$31.3M
$18.1M 0.7%
61,042
– –
AKRO
34
DELISTED
Akero Therapeutics
AKRO
$17.6M 0.68%
831,495
– –
RARE icon
35
Ultragenyx Pharmaceutical
RARE
$1.27B
$16.8M 0.65%
+200,000
New +$16.3M
CGEM icon
36
Cullinan Oncology
CGEM
$1.33B
$16.6M 0.64%
1,074,082
– –
RAIN
37
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$15.1M 0.59%
1,175,000
– –
PRTA icon
38
Prothena Corp
PRTA
$423M
$14.8M 0.58%
300,000
– –
MIST icon
39
Milestone Pharmaceuticals
MIST
$116M
$14.7M 0.57%
2,238,861
-333,333
-13% -$2M
CNTA
40
DELISTED
Centessa Pharmaceuticals
CNTA
$14.1M 0.55%
1,251,137
-83,090
-6% -$1.12M
PNT
41
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$14M 0.54%
2,500,000
– –
BCAB
42
DELISTED
BIOATLA INC
BCAB
$13.5M 0.52%
13,727
– –
THRX
43
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$11.3M 0.44%
+892,057
New +$13.5M
BDTX icon
44
Black Diamond Therapeutics
BDTX
$111M
$10.7M 0.42%
2,014,858
– –
RNAC icon
45
Cartesian Therapeutics
RNAC
$241M
$10.7M 0.42%
109,469
– –
EPIX
46
DELISTED
ESSA Pharma
EPIX
$10.3M 0.4%
724,500
+37,500
+5% +$418K
CDAK
47
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$9.47M 0.37%
850,065
-180,000
-17% -$2.5M
NGM
48
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$8.86M 0.34%
500,000
– –
BMEA icon
49
Biomea Fusion
BMEA
$131M
$8.85M 0.34%
1,188,405
-900,000
-43% -$9.52M
LITS
50
Lite Strategy Inc
LITS
$35M
$7.78M 0.3%
145,655
– –
1
2
3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Boxer Capital held 95 positions worth $2.57B, down 10% from $2.86B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Boxer Capital withdrew a net $161M in Q4 2021, closing 24 positions and reducing 12 holdings. Its most notable exit was argenx, an estimated $51.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Boxer Capital opened a new position in State Street SPDR S&P Biotech ETF worth $246M.

  • Boxer Capital's largest Q4 2021 buy was State Street SPDR S&P Biotech ETF: 2,200,000 shares worth $246M.
  • Boxer Capital added most to Relay Therapeutics in Q4 2021, an estimated $43.5M increase.
  • Boxer Capital's biggest Q4 2021 reduction was BeOne Medicines Ltd, cutting an estimated $89.2M.
  • Boxer Capital fully exited argenx in Q4 2021, selling an estimated $51.6M.
  • Boxer Capital's ten largest holdings make up 56% of its $2.57B portfolio in Q4 2021.
  • Boxer Capital opened 7 new positions and closed 24 in Q4 2021.
  • Boxer Capital's portfolio value fell 10% quarter-over-quarter to $2.57B.

Based on Boxer Capital's 13F filing for Q4 2021, filed 14 Feb 2022.